APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Coagulation Factor Ⅷ

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human Coagulation Factor Ⅷ Market Analysis and Forecast 2026-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchHuman Coagulation Factor Ⅷ Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Coagulation Factor Ⅷ Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Human Coagulation Factor Ⅷ Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Coagulation Factor Ⅷ Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Coagulation Factor Ⅷ Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Human Coagulation Factor Ⅷ market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Coagulation Factor Ⅷ is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human Coagulation Factor Ⅷ is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human Coagulation Factor Ⅷ is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human Coagulation Factor Ⅷ is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Human Coagulation Factor Ⅷ include Taibang Bio, Guangdong Shuanglin, Shanghai Laishi, GreenCross, Pfizer, Pfizer, Hualan Bio, Bayer and Baxter, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Coagulation Factor Ⅷ, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Coagulation Factor Ⅷ, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Coagulation Factor Ⅷ, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Coagulation Factor Ⅷ revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Coagulation Factor Ⅷ market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Human Coagulation Factor Ⅷ revenue, projected growth trends, production technology, application and end-user industry.

Human Coagulation Factor Ⅷ Segment by Company

Taibang Bio

Guangdong Shuanglin

Shanghai Laishi

GreenCross

Pfizer

Pfizer

Hualan Bio

Bayer

Baxter

Octapharma

Grifols

CSL Behring

Human Coagulation Factor Ⅷ Segment by Type

Recombinant Factor VIII

Human Factor VIII

Human Coagulation Factor Ⅷ Segment by Application

Relvent Bleeding Diseases

Hemophilia A

Human Coagulation Factor Ⅷ Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor Ⅷ.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Human Coagulation Factor Ⅷ in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Human Coagulation Factor Ⅷ company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Coagulation Factor Ⅷ revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Coagulation Factor Ⅷ Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Recombinant Factor VIII Major Player Table 3. Human Factor VIII Major Player Table 4. Global Human Coagulation Factor Ⅷ Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Relvent Bleeding Diseases Major Player Table 6. Hemophilia A Major Player Table 7. Human Coagulation Factor Ⅷ Industry Trends Table 8. Human Coagulation Factor Ⅷ Industry Drivers Table 9. Human Coagulation Factor Ⅷ Industry Opportunities and Challenges Table 10. Human Coagulation Factor Ⅷ Industry Restraints Table 11. Global Human Coagulation Factor Ⅷ Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Human Coagulation Factor Ⅷ Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Human Coagulation Factor Ⅷ Market Share by Region (2021-2026) Table 14. Global Human Coagulation Factor Ⅷ Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Human Coagulation Factor Ⅷ Market Share by Region (2027-2032) Table 16. Global Human Coagulation Factor Ⅷ Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Human Coagulation Factor Ⅷ Revenue Market Share by Players (2021-2026) Table 18. Global Human Coagulation Factor Ⅷ Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Human Coagulation Factor Ⅷ Key Players Headquarters & Area Served Table 20. Global Human Coagulation Factor Ⅷ Players, Product Type & Application Table 21. Global Human Coagulation Factor Ⅷ Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Human Coagulation Factor Ⅷ by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Human Coagulation Factor Ⅷ Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Coagulation Factor Ⅷ Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Human Coagulation Factor Ⅷ Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Human Coagulation Factor Ⅷ Revenue Market Share by Type (2021-2026) Table 28. Global Human Coagulation Factor Ⅷ Revenue Market Share by Type (2027-2032) Table 29. Global Human Coagulation Factor Ⅷ Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Human Coagulation Factor Ⅷ Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Human Coagulation Factor Ⅷ Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Human Coagulation Factor Ⅷ Revenue Market Share by Application (2021-2026) Table 33. Global Human Coagulation Factor Ⅷ Revenue Market Share by Application (2027-2032) Table 34. Taibang Bio Company Information Table 35. Taibang Bio Business Overview Table 36. Taibang Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Taibang Bio Human Coagulation Factor Ⅷ Product Portfolio Table 38. Taibang Bio Recent Development Table 39. Guangdong Shuanglin Company Information Table 40. Guangdong Shuanglin Business Overview Table 41. Guangdong Shuanglin Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Guangdong Shuanglin Human Coagulation Factor Ⅷ Product Portfolio Table 43. Guangdong Shuanglin Recent Development Table 44. Shanghai Laishi Company Information Table 45. Shanghai Laishi Business Overview Table 46. Shanghai Laishi Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Shanghai Laishi Human Coagulation Factor Ⅷ Product Portfolio Table 48. Shanghai Laishi Recent Development Table 49. GreenCross Company Information Table 50. GreenCross Business Overview Table 51. GreenCross Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. GreenCross Human Coagulation Factor Ⅷ Product Portfolio Table 53. GreenCross Recent Development Table 54. Pfizer Company Information Table 55. Pfizer Business Overview Table 56. Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Pfizer Human Coagulation Factor Ⅷ Product Portfolio Table 58. Pfizer Recent Development Table 59. Pfizer Company Information Table 60. Pfizer Business Overview Table 61. Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Pfizer Human Coagulation Factor Ⅷ Product Portfolio Table 63. Pfizer Recent Development Table 64. Hualan Bio Company Information Table 65. Hualan Bio Business Overview Table 66. Hualan Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Hualan Bio Human Coagulation Factor Ⅷ Product Portfolio Table 68. Hualan Bio Recent Development Table 69. Bayer Company Information Table 70. Bayer Business Overview Table 71. Bayer Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Bayer Human Coagulation Factor Ⅷ Product Portfolio Table 73. Bayer Recent Development Table 74. Baxter Company Information Table 75. Baxter Business Overview Table 76. Baxter Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Baxter Human Coagulation Factor Ⅷ Product Portfolio Table 78. Baxter Recent Development Table 79. Octapharma Company Information Table 80. Octapharma Business Overview Table 81. Octapharma Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Octapharma Human Coagulation Factor Ⅷ Product Portfolio Table 83. Octapharma Recent Development Table 84. Grifols Company Information Table 85. Grifols Business Overview Table 86. Grifols Human Coagulation Factor Ⅷ Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Grifols Human Coagulation Factor Ⅷ Product Portfolio Table 88. Grifols Recent Development Table 89. CSL Behring Company Information Table 90. CSL Behring Business Overview Table 91. CSL Behring Human Coagulation Factor Ⅷ Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. CSL Behring Human Coagulation Factor Ⅷ Product Portfolio Table 93. CSL Behring Recent Development Table 94. North America Human Coagulation Factor Ⅷ Revenue by Type (2021-2026) & (US$ Million) Table 95. North America Human Coagulation Factor Ⅷ Revenue by Type (2027-2032) & (US$ Million) Table 96. North America Human Coagulation Factor Ⅷ Revenue by Application (2021-2026) & (US$ Million) Table 97. North America Human Coagulation Factor Ⅷ Revenue by Application (2027-2032) & (US$ Million) Table 98. North America Human Coagulation Factor Ⅷ Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. North America Human Coagulation Factor Ⅷ Revenue by Country (2021-2026) & (US$ Million) Table 100. North America Human Coagulation Factor Ⅷ Revenue by Country (US$ Million) & (2027-2032) Table 101. Europe Human Coagulation Factor Ⅷ Revenue by Type (2021-2026) & (US$ Million) Table 102. Europe Human Coagulation Factor Ⅷ Revenue by Type (2027-2032) & (US$ Million) Table 103. Europe Human Coagulation Factor Ⅷ Revenue by Application (2021-2026) & (US$ Million) Table 104. Europe Human Coagulation Factor Ⅷ Revenue by Application (2027-2032) & (US$ Million) Table 105. Europe Human Coagulation Factor Ⅷ Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Europe Human Coagulation Factor Ⅷ Revenue by Country (2021-2026) & (US$ Million) Table 107. Europe Human Coagulation Factor Ⅷ Revenue by Country (US$ Million) & (2027-2032) Table 108. China Human Coagulation Factor Ⅷ Revenue by Type (2021-2026) & (US$ Million) Table 109. China Human Coagulation Factor Ⅷ Revenue by Type (2027-2032) & (US$ Million) Table 110. China Human Coagulation Factor Ⅷ Revenue by Application (2021-2026) & (US$ Million) Table 111. China Human Coagulation Factor Ⅷ Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Human Coagulation Factor Ⅷ Revenue by Type (2021-2026) & (US$ Million) Table 113. Asia Human Coagulation Factor Ⅷ Revenue by Type (2027-2032) & (US$ Million) Table 114. Asia Human Coagulation Factor Ⅷ Revenue by Application (2021-2026) & (US$ Million) Table 115. Asia Human Coagulation Factor Ⅷ Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Human Coagulation Factor Ⅷ Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Asia Human Coagulation Factor Ⅷ Revenue by Region (US$ Million) & (2021-2026) Table 118. Asia Human Coagulation Factor Ⅷ Revenue by Region (US$ Million) & (2027-2032) Table 119. SAMEA Human Coagulation Factor Ⅷ Revenue by Type (2021-2026) & (US$ Million) Table 120. SAMEA Human Coagulation Factor Ⅷ Revenue by Type (2027-2032) & (US$ Million) Table 121. SAMEA Human Coagulation Factor Ⅷ Revenue by Application (2021-2026) & (US$ Million) Table 122. SAMEA Human Coagulation Factor Ⅷ Revenue by Application (2027-2032) & (US$ Million) Table 123. SAMEA Human Coagulation Factor Ⅷ Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. SAMEA Human Coagulation Factor Ⅷ Revenue by Country (2021-2026) & (US$ Million) Table 125. SAMEA Human Coagulation Factor Ⅷ Revenue by Country (US$ Million) & (2027-2032) Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Human Coagulation Factor Ⅷ Image Figure 2. Global Human Coagulation Factor Ⅷ Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Coagulation Factor Ⅷ Market Size Share 2021 VS 2025 VS 2032 Figure 4. Recombinant Factor VIII Image Figure 5. Human Factor VIII Image Figure 6. Global Human Coagulation Factor Ⅷ Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Human Coagulation Factor Ⅷ Market Size Share 2021 VS 2025 VS 2032 Figure 8. Relvent Bleeding Diseases Image Figure 9. Hemophilia A Image Figure 10. Global Human Coagulation Factor Ⅷ Market Size (US$ Million) & (2021-2032) Figure 11. Global Human Coagulation Factor Ⅷ Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Human Coagulation Factor Ⅷ Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Human Coagulation Factor Ⅷ Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Human Coagulation Factor Ⅷ Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Human Coagulation Factor Ⅷ Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Human Coagulation Factor Ⅷ Revenue Market Share by Type (2021-2032) Figure 18. Global Human Coagulation Factor Ⅷ Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Human Coagulation Factor Ⅷ Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Human Coagulation Factor Ⅷ Revenue Market Share by Application (2021-2032) Figure 21. North America Human Coagulation Factor Ⅷ Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032) Figure 23. North America Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032) Figure 24. North America Human Coagulation Factor Ⅷ Revenue Share by Country (2021-2032) Figure 25. United States Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Human Coagulation Factor Ⅷ Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032) Figure 30. Europe Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032) Figure 31. Europe Human Coagulation Factor Ⅷ Revenue Share by Country (2021-2032) Figure 32. Germany Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Human Coagulation Factor Ⅷ Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032) Figure 42. China Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032) Figure 43. Asia Human Coagulation Factor Ⅷ Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032) Figure 45. Asia Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032) Figure 46. Asia Human Coagulation Factor Ⅷ Revenue Share by Region (2021-2032) Figure 47. Japan Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Human Coagulation Factor Ⅷ Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032) Figure 55. SAMEA Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032) Figure 56. SAMEA Human Coagulation Factor Ⅷ Revenue Share by Country (2021-2032) Figure 57. Brazil Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Human Coagulation Factor Ⅷ Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Factor VIII
  • Human Factor VIII
Applications
  • Relvent Bleeding Diseases
  • Hemophilia A
Companies covered
  • Taibang Bio
  • Guangdong Shuanglin
  • Shanghai Laishi
  • GreenCross
  • Pfizer
  • Pfizer
  • Hualan Bio
  • Bayer
  • Baxter
  • Octapharma
  • Grifols
  • CSL Behring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Coagulation Factor Ⅷ Market by Type
  3. 1.2.1 Global Human Coagulation Factor Ⅷ Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Recombinant Factor VIII
  5. 1.2.3 Human Factor VIII
  6. 1.3 Human Coagulation Factor Ⅷ Market by Application
  7. 1.3.1 Global Human Coagulation Factor Ⅷ Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Relvent Bleeding Diseases
  9. 1.3.3 Hemophilia A
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Human Coagulation Factor Ⅷ Market Dynamics
  1. 2.1 Human Coagulation Factor Ⅷ Industry Trends
  2. 2.2 Human Coagulation Factor Ⅷ Industry Drivers
  3. 2.3 Human Coagulation Factor Ⅷ Industry Opportunities and Challenges
  4. 2.4 Human Coagulation Factor Ⅷ Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Human Coagulation Factor Ⅷ Market Perspective (2021-2032)
  2. 3.2 Global Human Coagulation Factor Ⅷ Growth Trends by Region
  3. 3.2.1 Global Human Coagulation Factor Ⅷ Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Coagulation Factor Ⅷ Market Size by Region (2021-2026)
  5. 3.2.3 Global Human Coagulation Factor Ⅷ Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Human Coagulation Factor Ⅷ Revenue by Players
  2. 4.1.1 Global Human Coagulation Factor Ⅷ Revenue by Players (2021-2026)
  3. 4.1.2 Global Human Coagulation Factor Ⅷ Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Human Coagulation Factor Ⅷ Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Coagulation Factor Ⅷ Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Human Coagulation Factor Ⅷ Key Players Headquarters & Area Served
  7. 4.4 Global Human Coagulation Factor Ⅷ Players, Product Type & Application
  8. 4.5 Global Human Coagulation Factor Ⅷ Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Human Coagulation Factor Ⅷ Market CR5 and HHI
  11. 4.6.3 2025 Human Coagulation Factor Ⅷ Tier 1, Tier 2, and Tier 3
5 Human Coagulation Factor Ⅷ Market Size by Type
  1. 5.1 Global Human Coagulation Factor Ⅷ Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Human Coagulation Factor Ⅷ Revenue by Type (2021-2032)
  3. 5.3 Global Human Coagulation Factor Ⅷ Revenue Market Share by Type (2021-2032)
6 Human Coagulation Factor Ⅷ Market Size by Application
  1. 6.1 Global Human Coagulation Factor Ⅷ Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Human Coagulation Factor Ⅷ Revenue by Application (2021-2032)
  3. 6.3 Global Human Coagulation Factor Ⅷ Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Taibang Bio
  2. 7.1.1 Taibang Bio Company Information
  3. 7.1.2 Taibang Bio Business Overview
  4. 7.1.3 Taibang Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Taibang Bio Human Coagulation Factor Ⅷ Product Portfolio
  6. 7.1.5 Taibang Bio Recent Developments
  7. 7.2 Guangdong Shuanglin
  8. 7.2.1 Guangdong Shuanglin Company Information
  9. 7.2.2 Guangdong Shuanglin Business Overview
  10. 7.2.3 Guangdong Shuanglin Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Guangdong Shuanglin Human Coagulation Factor Ⅷ Product Portfolio
  12. 7.2.5 Guangdong Shuanglin Recent Developments
  13. 7.3 Shanghai Laishi
  14. 7.3.1 Shanghai Laishi Company Information
  15. 7.3.2 Shanghai Laishi Business Overview
  16. 7.3.3 Shanghai Laishi Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shanghai Laishi Human Coagulation Factor Ⅷ Product Portfolio
  18. 7.3.5 Shanghai Laishi Recent Developments
  19. 7.4 GreenCross
  20. 7.4.1 GreenCross Company Information
  21. 7.4.2 GreenCross Business Overview
  22. 7.4.3 GreenCross Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GreenCross Human Coagulation Factor Ⅷ Product Portfolio
  24. 7.4.5 GreenCross Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Hualan Bio
  38. 7.7.1 Hualan Bio Company Information
  39. 7.7.2 Hualan Bio Business Overview
  40. 7.7.3 Hualan Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Hualan Bio Human Coagulation Factor Ⅷ Product Portfolio
  42. 7.7.5 Hualan Bio Recent Developments
  43. 7.8 Bayer
  44. 7.8.1 Bayer Company Information
  45. 7.8.2 Bayer Business Overview
  46. 7.8.3 Bayer Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bayer Human Coagulation Factor Ⅷ Product Portfolio
  48. 7.8.5 Bayer Recent Developments
  49. 7.9 Baxter
  50. 7.9.1 Baxter Company Information
  51. 7.9.2 Baxter Business Overview
  52. 7.9.3 Baxter Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Baxter Human Coagulation Factor Ⅷ Product Portfolio
  54. 7.9.5 Baxter Recent Developments
  55. 7.10 Octapharma
  56. 7.10.1 Octapharma Company Information
  57. 7.10.2 Octapharma Business Overview
  58. 7.10.3 Octapharma Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Octapharma Human Coagulation Factor Ⅷ Product Portfolio
  60. 7.10.5 Octapharma Recent Developments
  61. 7.11 Grifols
  62. 7.11.1 Grifols Company Information
  63. 7.11.2 Grifols Business Overview
  64. 7.11.3 Grifols Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Grifols Human Coagulation Factor Ⅷ Product Portfolio
  66. 7.11.5 Grifols Recent Developments
  67. 7.12 CSL Behring
  68. 7.12.1 CSL Behring Company Information
  69. 7.12.2 CSL Behring Business Overview
  70. 7.12.3 CSL Behring Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  71. 7.12.4 CSL Behring Human Coagulation Factor Ⅷ Product Portfolio
  72. 7.12.5 CSL Behring Recent Developments
8 North America
  1. 8.1 North America Human Coagulation Factor Ⅷ Revenue (2021-2032)
  2. 8.2 North America Human Coagulation Factor Ⅷ Revenue by Type (2021-2032)
  3. 8.2.1 North America Human Coagulation Factor Ⅷ Revenue by Type (2021-2026)
  4. 8.2.2 North America Human Coagulation Factor Ⅷ Revenue by Type (2027-2032)
  5. 8.3 North America Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032)
  6. 8.4 North America Human Coagulation Factor Ⅷ Revenue by Application (2021-2032)
  7. 8.4.1 North America Human Coagulation Factor Ⅷ Revenue by Application (2021-2026)
  8. 8.4.2 North America Human Coagulation Factor Ⅷ Revenue by Application (2027-2032)
  9. 8.5 North America Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032)
  10. 8.6 North America Human Coagulation Factor Ⅷ Revenue by Country
  11. 8.6.1 North America Human Coagulation Factor Ⅷ Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Human Coagulation Factor Ⅷ Revenue by Country (2021-2026)
  13. 8.6.3 North America Human Coagulation Factor Ⅷ Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Human Coagulation Factor Ⅷ Revenue (2021-2032)
  2. 9.2 Europe Human Coagulation Factor Ⅷ Revenue by Type (2021-2032)
  3. 9.2.1 Europe Human Coagulation Factor Ⅷ Revenue by Type (2021-2026)
  4. 9.2.2 Europe Human Coagulation Factor Ⅷ Revenue by Type (2027-2032)
  5. 9.3 Europe Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032)
  6. 9.4 Europe Human Coagulation Factor Ⅷ Revenue by Application (2021-2032)
  7. 9.4.1 Europe Human Coagulation Factor Ⅷ Revenue by Application (2021-2026)
  8. 9.4.2 Europe Human Coagulation Factor Ⅷ Revenue by Application (2027-2032)
  9. 9.5 Europe Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032)
  10. 9.6 Europe Human Coagulation Factor Ⅷ Revenue by Country
  11. 9.6.1 Europe Human Coagulation Factor Ⅷ Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Human Coagulation Factor Ⅷ Revenue by Country (2021-2026)
  13. 9.6.3 Europe Human Coagulation Factor Ⅷ Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Human Coagulation Factor Ⅷ Revenue (2021-2032)
  2. 10.2 China Human Coagulation Factor Ⅷ Revenue by Type (2021-2032)
  3. 10.2.1 China Human Coagulation Factor Ⅷ Revenue by Type (2021-2026)
  4. 10.2.2 China Human Coagulation Factor Ⅷ Revenue by Type (2027-2032)
  5. 10.3 China Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032)
  6. 10.4 China Human Coagulation Factor Ⅷ Revenue by Application (2021-2032)
  7. 10.4.1 China Human Coagulation Factor Ⅷ Revenue by Application (2021-2026)
  8. 10.4.2 China Human Coagulation Factor Ⅷ Revenue by Application (2027-2032)
  9. 10.5 China Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Coagulation Factor Ⅷ Revenue (2021-2032)
  2. 11.2 Asia Human Coagulation Factor Ⅷ Revenue by Type (2021-2032)
  3. 11.2.1 Asia Human Coagulation Factor Ⅷ Revenue by Type (2021-2026)
  4. 11.2.2 Asia Human Coagulation Factor Ⅷ Revenue by Type (2027-2032)
  5. 11.3 Asia Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032)
  6. 11.4 Asia Human Coagulation Factor Ⅷ Revenue by Application (2021-2032)
  7. 11.4.1 Asia Human Coagulation Factor Ⅷ Revenue by Application (2021-2026)
  8. 11.4.2 Asia Human Coagulation Factor Ⅷ Revenue by Application (2027-2032)
  9. 11.5 Asia Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032)
  10. 11.6 Asia Human Coagulation Factor Ⅷ Revenue by Country
  11. 11.6.1 Asia Human Coagulation Factor Ⅷ Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Human Coagulation Factor Ⅷ Revenue by Country (2021-2026)
  13. 11.6.3 Asia Human Coagulation Factor Ⅷ Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Coagulation Factor Ⅷ Revenue (2021-2032)
  2. 12.2 SAMEA Human Coagulation Factor Ⅷ Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Human Coagulation Factor Ⅷ Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Human Coagulation Factor Ⅷ Revenue by Type (2027-2032)
  5. 12.3 SAMEA Human Coagulation Factor Ⅷ Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Human Coagulation Factor Ⅷ Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Human Coagulation Factor Ⅷ Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Human Coagulation Factor Ⅷ Revenue by Application (2027-2032)
  9. 12.5 SAMEA Human Coagulation Factor Ⅷ Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Human Coagulation Factor Ⅷ Revenue by Country
  11. 12.6.1 SAMEA Human Coagulation Factor Ⅷ Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Human Coagulation Factor Ⅷ Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Human Coagulation Factor Ⅷ Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst